| Literature DB >> 32649877 |
Jun-Yu Xu1, Chunchao Zhang2, Xiang Wang3, Linhui Zhai1, Yiming Ma4, Yousheng Mao5, Kun Qian6, Changqing Sun7, Zhiwei Liu8, Shangwen Jiang1, Minghui Wang3, Lin Feng3, Lei Zhao1, Ping Liu1, Bo Wang4, Xin Zhao6, Hui Xie7, Xiaoyun Yang4, Liyuan Zhao4, Yafei Chang4, Jingya Jia4, Xijun Wang3, Yimin Zhang4, Yaru Wang3, Yikun Yang5, Zhixiang Wu1, Longhai Yang5, Bin Liu1, Teng Zhao6, Shengguo Ren9, Aihua Sun2, Yang Zhao2, Wantao Ying2, Fei Wang9, Guangshun Wang10, Yi Zhang6, Shujun Cheng3, Jun Qin2, Xiaohong Qian2, Yi Wang11, Jing Li12, Fuchu He13, Ting Xiao14, Minjia Tan15.
Abstract
Genomic studies of lung adenocarcinoma (LUAD) have advanced our understanding of the disease's biology and accelerated targeted therapy. However, the proteomic characteristics of LUAD remain poorly understood. We carried out a comprehensive proteomics analysis of 103 cases of LUAD in Chinese patients. Integrative analysis of proteome, phosphoproteome, transcriptome, and whole-exome sequencing data revealed cancer-associated characteristics, such as tumor-associated protein variants, distinct proteomics features, and clinical outcomes in patients at an early stage or with EGFR and TP53 mutations. Proteome-based stratification of LUAD revealed three subtypes (S-I, S-II, and S-III) related to different clinical and molecular features. Further, we nominated potential drug targets and validated the plasma protein level of HSP 90β as a potential prognostic biomarker for LUAD in an independent cohort. Our integrative proteomics analysis enables a more comprehensive understanding of the molecular landscape of LUAD and offers an opportunity for more precise diagnosis and treatment.Entities:
Keywords: biomarker; clinical outcome; drug target; genomics; lung adenocarcinoma; mass spectrometry; phosphoproteomics; precision medicine; proteomics; regulatory network
Mesh：
Substances：
Year: 2020 PMID： 32649877 DOI： 10.1016/j.cell.2020.05.043
Source DB: PubMed Journal: Cell ISSN： 0092-8674 Impact factor: 41.582